Expressions of Endocan in Patients with Meningiomas and Gliomas

Table 2

Overall survival and endocan levels (ng/mg protein) in patients studied here.

Number	⁢Endocan levels in the groups				Follow-up (months); MGs/LGGs/HGGs
	Controls	MGs	LGGs	HGGs
1	8.12	12.27	14.55	15.62	36/24/9 (D)
2	9.76	14.50	12.65	19.05	36/48/36
3	11.08	12.98	13.20	22.30	12/36/60
4	10.91	11.62	18.90	17.50	36/12/12 (D)
5	10.72	12.02	11.77	14.36	16/48/15 (D)
6	7.92	10.91	12.27	12.78	60/13/36
7	8.41	9.23	10.78	18.90	24/24/12 (D)
8	8.77	11.77	12.98	14.55	36/14/15 (D)
9	11.20	10.72	9.25	16.71	36/15/18 (D)
10	10.32	9.21	17.62	17.62	36/18/12 (D)
11	8.41	11.21	10.91	15.02	36/24/30 (D)
12	7.65	12.36	9.23	16.71	23/24/30
13	12.04	14.32	14.52	12.65	13/24/42
14	8.62	10.27	14.60	10.91	23/16/18
15	11.08	11.41	17.30	18.09	12/36/12 (D)
16	—	14.55	14.50	17.52	13/24/13 (D)
17	—	14.36	18.62	15.94	24/19/12 (D)
18	—	12.50	16.02	15.94	36/26/15
19	—	10.91	14.50	14.20	12/13/16
20	—	10.65	—	17.60	24/—/18

D: died; HGGs: high-grade gliomas; LGGs: low-grade gliomas; MGs: meningiomas.
denotes grade-IV astrocytoma (glioblastoma multiforme).